AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
47.94
+2.51 (5.52%)
At close: Oct 21, 2026, 4:00 PM EDT
47.67
-0.27 (-0.56%)
After-hours: Oct 21, 2026, 7:40 PM EDT
AnaptysBio Revenue
AnaptysBio had revenue of $27.49M in the quarter ending June 30, 2026, with 23.47% growth. This brings the company's total for the last twelve months to $237.61M, up 92.92% year-over-year. In the year 2025, AnaptysBio had annual revenue of $234.60M with 157.01% growth. That makes AnaptysBio the 22,185th largest company in the world by revenue and 3,248th in the United States.
Revenue (ttm)
$237.61M
Revenue Growth
+92.92%
P/S Ratio
13.51
Revenue / Employee
$1,020,077
Employees
104
Market Cap
1.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 234.60M | 143.32M | 157.01% |
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | 10.36M | 188.86% |
| Dec 31, 2013 | 5.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 440.00M |
| Ascentage Pharma Group International | 94.61M |
| Ocular Therapeutix | 52.06M |
| Nanobiotix | 13.15M |
| Taysha Gene Therapies | 5.49M |
| Inhibrx Biosciences | 1.30M |
ANAB News
- 2 days ago - AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer - TheFly
- 2 days ago - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewsWire
- 21 days ago - AnaptysBio price target lowered to $60 from $70 at JPMorgan - TheFly
- 4 weeks ago - AnaptysBio price target lowered to $81 from $90 at Leerink - TheFly
- 4 weeks ago - AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year - TheFly
- 4 weeks ago - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - AnaptysBio Earnings release: Q2 2026 - Filings
- 4 weeks ago - AnaptysBio Slides: Corporate presentation - Filings